Deeper Knowledge, Faster

  • Analyze global market entry opportunities
  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

US Department of Justice
US Army
Cantor Fitzgerald
Queensland Health

Generated: November 25, 2017

DrugPatentWatch Database Preview

Details for Patent: ► Subscribe

« Back to Dashboard

Details for Patent: ► Subscribe

Title:GH secretagogues and uses thereof
Abstract: The invention relates to use of a GH secretagogue (e.g. GRF or an analog thereof) for (1) altering a lipid parameter in a subject; (2) altering a body composition parameter in a subject, (3) treating a condition characterized by deficient or decreased bone formation in a subject (4) improving daytime vigilance and/or cognitive function in a subject, (5) improving a metabolic condition in a subject, (6) improving anabolism in a catabolic condition in a subject, and/or (7) improving and/or reconstituting immune function in a subject.
Inventor(s): Abribat; Thierry (St-Foy-les-Lyon, FR), De Villers; Andre (Outremont, CA), Chapdelaine; Alcide (Ile des Soeurs, CA), Allas; Soraya (Iles des Soeurs, CA), Gravel; Denis (Saint-Lambert, CA)
Assignee: Theratechnologies Inc. (Montreal, CA)
Filing Date:Sep 26, 2008
Application Number:12/239,697
Claims:1. A method of improving cognitive function in a subject suffering from mild cognitive impairment, said method comprising administering to said subject: (a) (hexenoyl trans-3)hGRF(1-44)NH.sub.2; or (b) a composition comprising (hexenoyl trans-3)hGRF(1-44)NH.sub.2 and a pharmaceutically acceptable carrier.

2. The method of claim 1, wherein said cognitive function is thinking, reasoning, problem solving or memory.

3. The method of claim 1, wherein said (hexenoyl trans-3)hGRF(1-44)NH.sub.2 is administered at a dose of about 0.0001 to 2 mg.

4. The method of claim 3, wherein said (hexenoyl trans-3)hGRF(1-44)NH.sub.2 is administered at a dose of about 0.1 mg or about 1 mg.

5. The method of claim 4, wherein said (hexenoyl trans-3)hGRF(1-44)NH.sub.2 is administered at a dose of about 1 mg.

6. The method of claim 1, wherein said (hexenoyl trans-3)hGRF(1-44)NH.sub.2 or said composition is administered by an intravenous, oral, transdermal, subcutaneous, mucosal, intramuscular, intranasal, intrapulmonary, parenteral, intrarectal or topical route.

7. The method of claim 6, wherein said (hexenoyl trans-3)hGRF(1-44)NH.sub.2 or said composition is administered by a subcutaneous route.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

US Department of Justice
Express Scripts
Argus Health
Harvard Business School
US Army

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

Google Plus